Evidence map›Paper›PMID 40050776›Full record

ArticleBMC cancer2025

Luteolin as an adjuvant effectively enhanced the efficacy of adoptive tumor-specific CTLs therapy.

Zhiheng Lai, Yanyang Pang, Yujing Zhou, Leiyuan Chen, Kai Zheng, Shiguo Yuan, Wu Wang

Abstract read
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhiheng Lai *Department of Anorectal Surgery, Hainan Traditional Chinese Medicine Hospital, Hainan Medical University, Haikou, China.
Yanyang Pang *Department of Anorectal Surgery, Hainan Traditional Chinese Medicine Hospital, Hainan Medical University, Haikou, China.
Yujing Zhou *School of Public Health, Hainan Medical University, Haikou, China.
Leiyuan Chen *Department of Anorectal Surgery, Hainan Traditional Chinese Medicine Hospital, Hainan Medical University, Haikou, China.
Kai Zheng *Department of Orthopedics, Hainan Traditional Chinese Medicine Hospital, Hainan Medical University, Haikou, China.
Shiguo YuanDepartment of Orthopedics, Hainan Traditional Chinese Medicine Hospital, Hainan Medical University, Haikou, China. ysg@smu.edu.cn.
Wu WangDepartment of Anorectal Surgery, Hainan Traditional Chinese Medicine Hospital, Hainan Medical University, Haikou, China. lxd8860@163.com.

Funding

Hainan Provincial Health Industry Research Project 22A200106Hainan Provincial Natural Science Foundation of China 823MS150
6 · The paper itself

Abstract

backgroundLuteolin, a natural flavonoid compound, has demonstrated anti-inflammatory, antioxidant, and broad anti-tumor properties. Recent studies suggest that its anti-tumor effects are linked to enhanced CTL function-including proliferation, survival, and cytotoxicity-via inhibition of the YAP/Wnt signaling pathway in tumor cells. Consequently, luteolin has potential as an adjuvant in combination therapies with adoptive immunotherapy.

methodsThis study first assessed luteolin's tumor-inhibitory effects in vitro and in vivo using cytotoxicity assays, Transwell invasion tests, wound healing assays, and analyses of post-treatment tumor growth and survival time. Additionally, we explored whether luteolin combined with a DC/tumor fusion vaccine could synergistically enhance overall antitumor efficacy by boosting activation, proliferation, cytokines secretion, and cytotoxicity of effector T cells.

resultsOur findings indicate that luteolin, as a standalone agent, can inhibit the proliferation and invasion of colon and lung cancer cells both in vitro and in vivo to a certain extent. When combined with activated CTLs, it upregulated the expression of CD25 and CD69 in effector cells and resulted in higher levels of IL-2, TNF-α, and IFN-γ secretion in vitro. In vivo, this combination significantly curtailed subcutaneous tumor growth and extended the mean survival time of tumor-bearing mice (HCT116, A549), outperforming luteolin monotherapy. Furthermore, the efficacy of this combination therapy may be attributable to enhanced apoptosis in tumor cells, reduced proliferation, and decreased YAP expression.

conclusionThe combination of luteolin and DC/tumor fusion vaccine-activated CTLs presents a novel approach for cancer treatment. As an adjuvant, luteolin downregulates YAP expression in tumor cells, enhancing CTL proliferation, cytotoxicity, and survival, thus improving tumor recognition and selective targeting. This strategy is promising for safe and effective tumor treatment.

Indexed as

Adjuvants, ImmunologicImmunotherapy, AdoptiveLuteolinT-Lymphocytes, CytotoxicAnimalsCancer VaccinesCell Line, TumorCell ProliferationCombined Modality TherapyDendritic CellsFemaleHumansMiceXenograft Model Antitumor AssaysAdjuvants, ImmunologicCancer VaccinesLuteolin

Identifiers

PMID40050776
PMCPMC11887225

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.